Registered title, quoted from ClinicalTrials.gov
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06497530, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment for ES-SCLC;
Inclusion criterion 4
Women of childbearing potential(WOCBP) must have a negative serum pregnancy test before enrollment. WOCBP must use effective contraceptive measure during the trial drug treatment and for 6 months after the last administration. Male patients (with partners of WOCBP) must use effective contraceptive measure during the trial drug treatment and for 4 months after the last administration;
Inclusion criterion 14
Have a continuous response or stable disease according to RECIST 1.1 criteria after 4 cycles of induction therapy;
Inclusion criterion 16
Toxicity from the induction therapy phase has recovered to ≤ Grade 1;
Inclusion criterion 17
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
Inclusion criterion 3
Platelet count (PLT) ≥ 100×10\^9/L; Hemoglobin (Hb) ≥ 90 g/L; Absolute neutrophil count (ANC) ≥ 2.0×10\^9/L;
Inclusion criterion 7
Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0×upper limit of normal (ULN);
Inclusion criterion 8
Alkaline phosphatase (ALP) ≤ 5×ULN;
Inclusion criterion 9
Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;
Inclusion criterion 10
Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula);
Inclusion criterion 11
Creatine phosphokinase (CPK) ≤ 2.5×ULN;
Inclusion criterion 12
At least one measurable lesion (according to RECIST 1.1 criteria);
Inclusion criterion 5
Have a history of malignancies other than SCLC within 5 years before enrollment;
Exclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06497530, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria for the Induction Phase:
- Fully informed about the study and voluntarily signed a written informed consent form, and able to comply with the requirements and restrictions listed in the informed consent form;
- Male or female with age ≥ 18 years;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment for ES-SCLC;
- At least one measurable lesion (according to RECIST 1.1 criteria);
- Having adequate bone marrow, hepatic, renal and metabolic function, meaning the functional level of the organs meets the following requirements:
- Platelet count (PLT) ≥ 100×10\^9/L; Hemoglobin (Hb) ≥ 90 g/L; Absolute neutrophil count (ANC) ≥ 2.0×10\^9/L;
- Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0×upper limit of normal (ULN);
- Alkaline phosphatase (ALP) ≤ 5×ULN;
- Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;
- Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula);
- Creatine phosphokinase (CPK) ≤ 2.5×ULN;
- Albumin ≥ 3.0 g/dL.
- Women of childbearing potential(WOCBP) must have a negative serum pregnancy test before enrollment. WOCBP must use effective contraceptive measure during the trial drug treatment and for 6 months after the last administration. Male patients (with partners of WOCBP) must use effective contraceptive measure during the trial drug treatment and for 4 months after the last administration;
- Human immunodeficiency virus (HIV)-negative, with no active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Exclusion Criteria for the Induction Phase:
- Have a history of central nervous system (CNS) metastasis or related history;
- Have a history of active autoimmune disease or immunodeficiency, or related history;
- Have a history of malignancies other than SCLC within 5 years before enrollment;
- Previous treatment with immune checkpoint inhibitors or lurbinectedin;
- Have a history of idiopathic pulmonary fibrosis or pneumonia, or active pneumonia detected in CT screening;
- Treatment with any other investigational product within 28 days before enrollment.
Inclusion Criteria for the Maintenance Phase:
- Have a continuous response or stable disease according to RECIST 1.1 criteria after 4 cycles of induction therapy;
- Toxicity from the induction therapy phase has recovered to ≤ Grade 1;
- Have sufficient bone marrow and organ function.
Exclusion Criteria for the Maintenance Phase:
- Have a history of central nervous system (CNS) metastasis or related history;
- Has received chest consolidation radiotherapy;
- Severe infection within 2 weeks before enrollment.
Quoted from ClinicalTrials.gov, NCT06497530, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06497530, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.